Clinical trial TIBSER-LAM
Retrospective study of IDH1 mutated AML patients
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Autre
|
| Academic trial | Non |
| Sponsor | Servier |
| Inclusion criteria | 1. First record of AML diagnosis and/or start of first line (1L) treatment within the study recruitment period; (01JAN2021 TO 30JUN2025)2. At least 18 years of age at index date; 3. Patients who have a documented IDH1-gene mutated disease, demonstrated |
| Last update |